ArticleOncotarget2017
Trans-sialidase-based vaccine candidate protects against
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Dynamics and functional heterogeneity of FOXP3+ regulatory T cells in Trypanosoma cruzi infection: a systematic review.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Pooled it
- Immunoproteomic Identification and Vaccine Assessment ofVaccines · 2026Article
- The Role of Immunogenetics in the Host-Parasite Interaction of Chagas Disease: Implications for Personalized Medicine.Tropical medicine and infectious disease · 2025Review
- Article
- Integrating Cellular Immune Biomarkers with Machine Learning to Identify Potential Correlates of Protection for aVaccines · 2025Article
- Nasal vaccination againstFrontiers in immunology · 2025Article
- Towards a map of the immune system manipulation network byFrontiers in cellular and infection microbiology · 2025Review
- Sexual dimorphism-driven differences are overcome in a preclinical vaccine model againstFrontiers in immunology · 2025Article
- Article
- Control of myeloid-derived suppressor cell dynamics potentiates vaccine protection in multiple mouse models ofFrontiers in immunology · 2024Article
- Immunization With Lipopolysaccharide-Activated Dendritic Cells Generates a Specific CD8Frontiers in cellular and infection microbiology · 2022Article
- Myeloid-derived suppressor cells and vaccination against pathogens.Frontiers in cellular and infection microbiology · 2022Review
- The Case for the Development of a Chagas Disease Vaccine: Why? How? When?Tropical medicine and infectious disease · 2021Review
- Review
- Myeloid-Derived Suppressor Cells inFrontiers in cellular and infection microbiology · 2021Review
- Targeting Myeloid-Derived Suppressor Cells to Enhance a Trans-Sialidase-Based Vaccine AgainstFrontiers in cellular and infection microbiology · 2021Article
- Recombinant Mycobacterium bovis BCG is a promising platform to develop vaccines against Trypansoma cruzi infection.Clinical and experimental immunology · 2020Article
- A New Cage-Like Particle Adjuvant Enhances Protection of Foot-and-Mouth Disease Vaccine.Frontiers in veterinary science · 2020Article
- Understanding CD8Trends in parasitology · 2019Review
- Theft and Reception of Host Cell's Sialic Acid: Dynamics ofFrontiers in immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prophylactic and/or therapeutic vaccines have an important potential to control
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.